Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT ID: NCT04662866

Last Updated: 2021-04-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-10
• Study Completion Date: 2023-10-31

Brief Summary

This study will test the effect of four common oral anti-diabetic agents on hepatic insulin sensitivity in South Asian women with impaired glucose tolerance or impaired fasting glucose. In a 12-week, double-blind, randomized controlled intervention trial, the following drugs will be tested head-to-head: Metformin, Pioglitazone, Empagliflozin and Linagliptin. Additional, exploratory outcomes include whole body insulin sensitivity, insulin secretion and other markers of glucose and lipid metabolism, measured by the euglycemic clamp with stable isotope tracer dilution, indirect calorimetry and CT-measurements of abdominal adipose tissue compartment volumes and hepatic and pancreatic volume and attenuation.

The study is part of the DIASA - DIAbetes in South Asians - Research Programme, which aims to find ways to improve both prevention and treatment of type 2 diabetes in people of South Asian ethnicity.

Detailed Description

Background: South Asians (SA) have a high prevalence of type 2 diabetes (T2D). SA i Norway develop T2D approximately 10 years earlier than Nordic subjects (NO).T2D in SA is often poorly regulated with increased risk of complications.

Research hypothesis: South Asian subjects with Impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) have a high degree of hepatic insulin resistance. Treatment with certain oral antidiabetic drugs will improve hepatic insulin sensitivity more than others.

Primary objective: To assess which of four oral antidiabetic medications is most effective in improving hepatic insulin sensitivity in women of South Asian origin with IFG/IGT.

Study design: Single-center, randomized, double-blind intervention trial with 4 parallel treatment arms: 1) Metformin 2) Pioglitazone 3) Empagliflozin 4) Linagliptin.

Endogenous glucose production (EGP) and hepatic and whole body insulin sensitivity will be assessed by a 2-step euglycemic, hyperinsulinemic clamp with deuterated glucose tracer. In addition, glucose and lipid metabolism will be assessed by indirect calorimetry (IC), insulin secretion by an oral glucose tolerance test (OGTT), and fatty infiltration in liver by computer tomography (CT).

Recruitment: From South Asian women with IFG/IGT who participated in DIASA 1.

Duration of study: 14 weeks, with a total of four study visits, every 4 weeks, plus two CT scans, at baseline and 12 weeks, and one end of study follow-up telephone visit at 14 weeks. The project is expected to last a maximum of 3 years.

Study population: Women ≥ 18 years of age of South Asian ethnicity with IGT/IFG.

Criteria for evaluation: Efficacy outcome will include evaluation of change in EGP from baseline to 12 weeks. Laboratory parameters of glucose and lipid metabolism. Questionnaires with physical activity and food frequency. Safety and tolerability will be assessed by clinical adverse events and laboratory measurements from randomization to 14 weeks.

Primary outcome: Difference between treatment arms in change in EGP from baseline to 12 weeks.

Explorative outcomes: Difference between treatment arms in change from randomisation to 12 weeks in:

• whole body insulin sensitivity
• HbA1c
• glucose and lipid metabolism measured by IC
• fatty infiltration in liver and visceral adipose tissue.

Statistical Methods: One-way ANOVA, Multiple regression analyses, Paired samples t-tests, longitudinal analyses.

Conditions

Impaired Glucose Tolerance; Insulin Sensitivity; Glucose Metabolism Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Metformin

Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.

Group Type: ACTIVE_COMPARATOR

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Intervention Type: DRUG

Comparison of 4 different antihyperglycemic drugs

Empagliflozin

Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.

Group Type: ACTIVE_COMPARATOR

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Intervention Type: DRUG

Comparison of 4 different antihyperglycemic drugs

Linagliptin

Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.

Group Type: ACTIVE_COMPARATOR

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Intervention Type: DRUG

Comparison of 4 different antihyperglycemic drugs

Pioglitazone

Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.

Group Type: ACTIVE_COMPARATOR

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Intervention Type: DRUG

Comparison of 4 different antihyperglycemic drugs

Interventions

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Comparison of 4 different antihyperglycemic drugs

Intervention Type: DRUG

Other Intervention Names

biguanide, glitazone, sodium glucose transport inhibitor, dipeptidyl peptidase inhibitor

Eligibility Criteria

Inclusion Criteria

1. Able and willing to give informed consent

2. Woman ≥ 18 years of age

3. Of South Asian origin

4. Participated in the DIASA 1 study (i.e. has had previous gestational diabetes (GDM) in last pregnancy). A period of 3 months after the 3-year limit since childbirth after GDM is seen as acceptable for inclusion.

5. Impaired glucose tolerance (2-hour glucose value ≥7.8 and < 11.1 mmol/l) and/or impaired fasting glucose (fasting plasma glucose ≥ 6.1 and < 7.0 mmol/l) diagnosed in DIASA 1

4. Pregnant or fully lactating at randomisation or planned during study period.

5. Not willing to practice a highly effective birth control method* prior to initial dose, during study and for 2 weeks after the last administration of study drug.

6. Concomitant use of any antidiabetic medication

7. Concomitant use of fibrates or rifampicin

8. Radiological examinations iodine containing contrast the previous week before randomisation, or planned during the study period.

9. Known serious illness such as cancer (except in situ carcinoma) during past 5 years.

10. Previous radiation therapy directed towards the pelvic area.

11. Heart failure New York Heart Association (NYHA) class I-IV.

12. Estimated glomerulus filtration rate (eGFR) < 60 ml/min/1,73m2

13. Chronic liver disease with serum levels of aspartate aminotransferase (ASAT) or alanine amino transferase (ALAT) > 5 x upper limit of normal (ULN) or known impaired liver function (INR > 1.5, Albumin < 20 g/l, Bilirubin > 20 g/l.

14. Active infectious disease at inclusion

15. Use of systemic corticosteroids > 14 days within last 3 months before inclusion

16. Hypothyroidism where substitution with levothyroxine has not been stable for the last 3 months or with thyroid stimulating hormone (TSH) outside normal limits.

17. A history of bullous pemphigoid

18. A history of acute or chronic pancreatitis

19. Previous or present acute metabolic acidosis.

20. Known hypersensitivity to any of the active ingredients or additives in the study medication or placebo capsules.

21. Macroscopic haematuria not previously examined

22. History of major surgical procedures within 3 months prior to inclusion or planned during study period.

23. Any condition which in the investigator's opinion would jeopardize the subject's safety or compliance with the protocol.

• Birth control methods which may be considered as highly effective: Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system ( IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence.

Exclusion Criteria

1. Known type 2 diabetes

2. Known type 1 diabetes

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

The Research Council of Norway

OTHER

Sponsor Role: collaborator

Norwegian Diabetes Association

OTHER

Sponsor Role: collaborator

South-Eastern Norway Regional Health Authority

OTHER

Sponsor Role: collaborator

University of Oslo

OTHER

Sponsor Role: collaborator

University Hospital, Akershus

OTHER

Sponsor Role: collaborator

Vestre Viken Hospital Trust

OTHER

Sponsor Role: collaborator

University of Glasgow

OTHER

Sponsor Role: collaborator

Oslo University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Kåre Inge Birkeland

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kåre I Birkeland, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Professor

Locations

Oslo University Hospital, Aker Hospital

Oslo, , Norway

Site Status: RECRUITING

Countries

Norway

Central Contacts

Anita Suntharalingam, MD

Role: CONTACT

ansunt@ous-hf.no

+4722894745

Ellen Hillestad, Pharm.techn.

Role: CONTACT

elhill@ous-hf.no

+4722894000

Facility Contacts

Åse Halsne, RN

Role: primary

asehal@ous-hf.no

+4722894745

Other Identifiers

24993

Identifier Type: -

Identifier Source: org_study_id